Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1026-1028. doi: 10.1051/medsci/2019203. Epub 2020 Jan 6.

[Monoclonal antibodies for monogenic diseases: a 2019 update].

[Article in French; Abstract available in French from the publisher]

Author information

CHRU de Tours, Service de Médecine interne;,.
Université de Tours, France.
CHRU de Tours, Laboratoire d'Immunologie;,   - Université de Tours, France.
CHRU de Tours, Service de Médecine interne;,   - Université de Tours, France.


in English, French

Monogenic diseases are rare genetic diseases but they are numerous and display a highly variable degree of severity. First uses of monoclonal antibodies to treat monogenic diseases started in the 2000's and many clinical trials are ongoing. Anti-IL-1β therapies have greatly modified the outcome of auto-inflammatory diseases by modulating inflammatory response and reducing the risk of secondary amyloidosis. Anti-TNF-α are also used in such diseases. In atypical hemolytic and uremic syndrome due to deficiencies in the control of alternative complement pathway, eculizumab, an anti-C5 monoclonal antibody, has improved renal outcome in treated patients. More recently, lanadelumab, an anti-plasma kallikrein antibody, has reinforced the therapeutic arsenal in hereditary angioedema and burosumab, anti-FGF23, that of X-linked hypophosphatemia. Such examples reflect the importance of monoclonal antibody therapy of monogenic diseases, the interest of considering such an option as well as the need for future researches.


Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center